Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease - Top-Institutions - MDSpire

Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease

  • By

  • Stéphane Prange

  • Elise Metereau

  • Hélène Klinger

  • Marine Huddlestone

  • Melinda De Oliveira

  • Sandra Duperrier

  • Pierre Courault

  • Jérôme Redoute

  • Léon Tremblay

  • Véronique Sgambato

  • Sophie Lancelot

  • Stéphane Thobois

  • March 5, 2025

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Memory and Aging Center
    University of California, San Francisco (UCSF) Memory and Aging Center

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neuroimaging
    • Neuropsychiatry

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neuroimaging

  • #3

    Institut du Cerveau – ICM (Brain and Spine Institute), Paris
    Institut du Cerveau – ICM (Brain and Spine Institute), Paris

    Paris, Île-de-France

    Key Differentiators

    • Neurology
    • Neuroimaging
    • Neuropharmacology

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neuropsychiatry

Original Source(s)

Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease

  • by Stéphane Prange, Elise Metereau, Hélène Klinger, Marine Huddlestone, Melinda De Oliveira, Sandra Duperrier, Pierre Courault, Jérôme Redoute, Léon Tremblay, Véronique Sgambato, Sophie Lancelot, Stéphane Thobois

  • March 5, 2025

Related Content

Incidence of anxiety disorders following Parkinson's disease: a population-based cohort study

Neurobiological mechanisms of olfactory dysfunction: a ten-year bibliometric and visualization analysis

The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model